Co-crystals of non-steroidal anti-inflammatory drugs (NSAIDs): Insight toward formation, methods, and drug enhancement

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorUniversity of Strathclyde-
Autor(es): dc.creatorNascimento, André L.C.S. [UNESP]-
Autor(es): dc.creatorFernandes, Richard P. [UNESP]-
Autor(es): dc.creatorCharpentier, Maxime D.-
Autor(es): dc.creatorter Horst, Joop H.-
Autor(es): dc.creatorCaires, Flávio J. [UNESP]-
Autor(es): dc.creatorChorilli, Marlus [UNESP]-
Data de aceite: dc.date.accessioned2022-02-22T00:53:58Z-
Data de disponibilização: dc.date.available2022-02-22T00:53:58Z-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-10-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1016/j.partic.2021.03.015-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/208635-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/208635-
Descrição: dc.descriptionPharmaceutical co-crystals have been explored by many researchers as a strategy to optimize physicochemical properties of solid-state drugs. Their improvements of solubility, bioavailability, and the reduced tendency for phase transformation occurrence, are factors that highlight benefits of pharmaceutical co-crystals among other solid forms. According to the Biopharmaceutical Classification System (BCS), non-steroidal anti-inflammatory drugs (NSAIDs) are class II drugs, which have low aqueous solubility and therefore co-crystallization has the potential to optimize NSAID product properties. In this review, we highlight the recent progress made on NSAIDs co-crystals, their co-formers, synthesis, methods and use, while we underline some promising results on in vitro and in vivo co-crystal properties. A celecoxib-tramadol co-crystal reaches phase III clinical trials, showing greater analgesic activity than both individual APIs. The aqueous solubility of the co-crystal formed between L-proline and diclofenac is very high in comparison with the pure drug. Naproxen co-crystals with urea and thiourea have an increase of drug release of almost 60%. Co-crystal design brings a new perspective in drug development since the co-former used can also be a biologically active component allowing to combine different anti-inflammatory drugs, which have an incredible spectrum of application due to the analgesic, anti-pyretic and anti-inflammatory properties.-
Descrição: dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-
Descrição: dc.descriptionEngineering and Physical Sciences Research Council-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionSão Paulo State University (UNESP) School of Pharmaceutical Sciences-
Descrição: dc.descriptionSão Paulo State University (UNESP) Institute of Chemistry-
Descrição: dc.descriptionEPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation University of Strathclyde-
Descrição: dc.descriptionSão Paulo State University (UNESP) School of Sciences-
Descrição: dc.descriptionSão Paulo State University (UNESP) School of Pharmaceutical Sciences-
Descrição: dc.descriptionSão Paulo State University (UNESP) Institute of Chemistry-
Descrição: dc.descriptionSão Paulo State University (UNESP) School of Sciences-
Formato: dc.format227-241-
Idioma: dc.languageen-
Relação: dc.relationParticuology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectBioavailability-
Palavras-chave: dc.subjectCo-crystal discovery-
Palavras-chave: dc.subjectNSAIDs-
Palavras-chave: dc.subjectPharmaceutical co-crystals-
Palavras-chave: dc.subjectSupramolecular synthons-
Título: dc.titleCo-crystals of non-steroidal anti-inflammatory drugs (NSAIDs): Insight toward formation, methods, and drug enhancement-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.